Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-KRd in Primary Diagnosed High-risk Multiple Myeloma
NCT03104842Phase 2Active, not recruiting
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Aug 2017
- Primary completion
- May 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Minimal Residual Disease Negativity at 1 year. Started Aug 2017; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03104842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03104842.